A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Inclusion Criteria: * Histologically proven malignant pleural mesothelioma, epitheloid subtype * Recurrent after radical surgery or disease not considered suitable for radical treatment * EGFR IHC + as assessed by DAKO kit with at least 1% of cells showing staining * Performance status WHO 0 or 1 * Life expectancy \> 12 weeks * Weight loss \< 10% in last 3 months * Adequate bone marrow reserve, renal and hepatic function * Measurable disease (modified RECIST) * No prior chemotherapy * No prior or other malignancies, except if longer than 5 yrs ago and adequately treated or basocellular skin or in situ cervical cancer * No uncontrolled infection * Written informed consent. * Male/Female * \> 18 years Exclusion Criteria: * Evidence of brain or leptomeningeal metastases * Patients who are unable to interrupt aspirin, other nonsteroidal anti-inflammatory drugs for a 5-day period starting 2 days before administration of pemetrexed (8-day period for long acting agents such as piroxicam) * Patients that cannot be treated with folic acid and vitamin B 12 * Patients that cannot be treated with dexamethasone. * Presence of clinically detectable (by physical examination) third-space fluid collections, for example ascites of pleural effusions that cannot be controlled by drainage or other procedures prior to the study entry. * Use of investigational drugs